# Articles

# Pyrrolo[1,2-a]benzimidazole-Based Aziridinyl Quinones. A New Class of DNA Cleaving Agent Exhibiting G and A Base Specificity

Edward B. Skibo\* and William G. Schulz

Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona 85287-1604

Received March 12, 1993•

Pyrrolo[1,2-a]benzimiazole(PBI)-based aziridinyl quinones cleave DNA under reducing conditions specifically at G + A bases without any significant cleavage at C + T bases. The postulated mechanisms involve phosphate alkylation by the reductively activated aziridine to afford a hydrolytically labile phosphotriester as well as the classic N(7) purine alkylation followed by depurination and backbone cleavage. Evidence is presented that the phosphate alkylation mechanism could contribute. The PBIs possess a unique spectrum of cytotoxicity against cancer cells (inactive against leukemia but active against nonsmall cell lung, colon, CNS, melanoma, ovarian, and renal cancers). Also reported are results of *in vivo* antitumor activity screens.

# Introduction

The pyrrolo[1,2-a]benzimidazoles (PBIs) shown in Scheme I represent a new class of antitumor agent exhibiting activity against a variety of cancer cell lines.<sup>1-4</sup> These agents cleave DNA upon reduction of the quinone ring as a result of alkylation reactions by the aziridinylhydroquinone (inset of Scheme I). Questions posed dealt with the sequence specificity and mechanism of PBImediated DNA cleavage, and with the spectrum of PBI antitumor activity. In this report evidence is presented for PBI-mediated DNA cleavage at G and A bases. The cleavage process could involve N(7) purine alkylation followed by depurination and backbone cleavage<sup>5</sup> and/or a process involving phosphate alkylation followed by phosphotriester hydrolysis<sup>6</sup> (inset of Scheme I). Some experimental findings suggest that the phosphate alkylation mechanism could be in operation. The spectrum of PBI cytotoxicity observed in 60 cancer cell lines is quite unlike that of any clinically used antitumor agent. Antitumor studies in nude mice models indicate that the PBIs possess in vivo activity.

# **DNA Cleavage Studies**

The PBI-mediated cleavage of linear DNA was studied utilizing the  $3'^{32}P$ -end-labeled 514 bp RsaI/EcoRI and the 541 bp RsaI/ClaI restriction fragments of pBR322.<sup>7</sup> Shown in Figure 1 is an autoradiogram of the untreated RsaI/ClaI fragment (lane A), the EcoRI cut of this fragment to afford the 27bp EcoRI/ClaI fragment (lane B), and the Maxam-Gilbert G + A ladder<sup>8</sup> of the RsaI/ClaI fragment (lane C). Lanes A-C of Figure 1 indicate that the DNA used in these studies is pure. Figure 1 also shows the Maxam-Gilbert G + A cleavage of RsaI/ClaI (lane D) and the cleavage of this restriction fragment by reduced PBI-A (lane E). Comparisons of Lanes D and E indicate that DNA G + A cleavage occurs upon treatment with reduced PBI-A. Shown in Figure 2 is an autoradiogram of a slab gel obtained from PBI-A cleavage of the RsaI/EcoRI

0022-2623/93/1836-3050\$04.00/0

© 1993 American Chemical Society

fragment with only bases 4310-4332 shown.<sup>9</sup> Lane F shows a Maxam-Gilbert G ladder.<sup>8</sup> Lanes E, D, and B of Figure 1 show DNA which had been treated with reduced PBI-Aat concentrations of 1x, 2x, and 7x (x = 0.69 mM), respectively. The 2x lane shows enhanced cleavage compared to the 1x lane, while the 7x lane is showing signs of over cleavage. When cleavage was attempted in the presence of oxygen (lane C) or in the presence of dithionite without added PBI-A (lane A), no substantial cleavage DNA could be observed. Studies of reactions containing PBI-A and DNA only also did not produce cleavage. A parallel study of PBI-C mediated DNA cleavage (results not shown) provided identical results.

Mechanistic details of PBI-mediated DNA cleavage are now considered. The obvious mechanism for PBI-mediated DNA cleavage is N(7)-alkylation followed by depurination and backbone cleavage. Other aziridinylquimones can in fact cleave at G + A bases by this mechanism.<sup>5b</sup> Consistent with the depurination mechanism and a 5'phosphate cleavage terminus, the PBI cleavage ladders comigrate with the Maxam-Gilbert G and G + A ladders (Figures 1 and 2). In our attempt to isolate N(7)-purine adducts, we treated sonicated calf thymus DNA with reduced PBI-A and isolated "blue DNA" upon aeration and then precipitation from aqueous sodium acetate/ ethanol. Heating the drug-bound DNA at 50 °C in 0.2 M phosphate buffer for several hours afforded small amounts of drug hydrolysis products without any apparent release of N(7)-alkylated purine bases. These findings are analogous to those of Bannon and Verly,<sup>10</sup> who found that N(7)-DNA adducts are more hydrolytically labile than phosphate alkylation products.

In light of the above findings, the phosphate alkylation cleavage mechanism shown in the inset of Scheme I was considered as a possibility for PBI-mediated DNA cleavage. Such a mechanism is actually not out of the ordinary. Indeed, DNA treatment with the nitrosourea ENU<sup>6</sup> results in the formation of hydrolytically labile phosphotriesters. Alkyl methanesulfonates are known to alkylate DNA at both N(7)-positions and phosphate.<sup>10</sup> Furthermore, phosphate oxygens are known to be alkylated by aziridines.<sup>11</sup>

<sup>•</sup> Abstract published in Advance ACS Abstracts, September 1, 1993.

### Scheme I



To illustrate the latter point, we treated 5'-dAMP with a reduced PBI (Z-OH) and isolated the quinone adduct shown in Chart I after an aerobic workup.

According to the phosphate alkylation mechanism shown in Scheme I, the G + A specificity of PBI cleavage results from binding of reduced PBI in the major grooveat these bases. Interaction at G requires protonated drug (Chart I), whereas interaction at A requires neutral drug. Molecular modeling (insight II) of reduced PBI-A bound to A in the major groove with hydrogen bonds 1.5-2 Å in length with bond angles between 120 and 180° placed the aziridinyl carbon center ~3 Å from the phosphate oxygen (graphics not shown). The resulting adduct can cause DNA backbone cleavage by a nucleophilic displacement mechanism involving attack of the amino group (formerly the aziridinyl nitrogen center) on the phosphorus center, inset of Scheme I.

Phosphotriester analogues of DNA are usually quite stable to hydrolysis.<sup>10,12</sup> An exception is a  $\beta$ -hydroxyethyl phosphotriester, which undergoes hydrolysis at 37 °C by means of internal oxygen nucleophilic displacement at the phosphorus center.<sup>13</sup> Recently, Browne and Bruice<sup>14</sup> reported that even the phosphodiester, bis(8-hydroxyquinoline) phosphate, is readily hydrolyzed by internal nitrogen nucleophilic displacement at phosphate. Thus, there are precedents for the phosphate backbone cleavage mechanism shown in Scheme I. In fact, reduction of the quinone adduct shown in Chart I and incubation in anaerobic pH 7.4, 0.05 M tris buffer at 37°, results in slow phosphate hydrolysis to afford adenosine and 5'-dAMP (as followed by HPLC). If hydrolysis of the DNA phosphotriester adduct occurs in the 3' direction only, the observed 5'-phosphate cleavage termini will be formed (see Figures 1 and 2).

In the oxidized (quinone) form, both "blue DNA" and the adduct shown in Chart I are stable in pH 7 aqueous buffer at 37 °C. Indeed, in order to observe cleavage ladders with PBI-treated DNA, it was necessary to heat the DNA in a basic formamide loading solution at 95 °C for 2 min. The observed stability of oxidized PBI adducts is no doubt due to electron withdrawal by the quinone ring from the nitrogen involved in nucleophilic attack.

The conclusion of our mechanistic studies is that the phosphate alkylation mechanism is chemically feasible. We do not reject the N(7) purine alkylation as a possible coexisting cleavage mechanism, however.

#### Cytotoxicity and Antitumor Studies

Previous studies verified that PBI analogues can cause DNA single strand cleavage in myeloma cells in a dosedependent fashion.<sup>2</sup> The results cited in this article suggest that cellular DNA cleavage occurs at G + A bases upon reductive activation of the PBI analog. A structural relative of the PBI analogues, mitomycin C,<sup>15</sup> also requires reductive activation but alkylates the guanine amino group. Another structural relative, the aziridinylquinone AZQ,<sup>5</sup> alkylates the guanine N(7) position upon reductive activation. Despite some similarities with these antitumor agents, the PBI analogues have a unique spectrum of cytotoxic activity, which is now discussed in conjunction with the data in Table I.<sup>16</sup>

Found in Table Iis an  $LC_{50}$  mean graph obtained from screening PBI-A against a panel of 60 cancer cell lines ( $LC_{50}$  is the concentration needed for 50% cell kill).<sup>17</sup> The center line is the log of the mean  $LC_{50}$  value; bars to the right of the mean represent activity greater than the mean (lower log  $LC_{50}$  values), while bars to the left represent activity lower than the mean (higher log  $LC_{50}$  values). Other PBI analogues gave bar graphs similar to that shown in Table I.

The data in Table I show that PBI-A is virtually inactive against leukemia. Other cancers including nonsmall cell



**Figure 1.** Autoradiogram of 8% polyacrylamide/7 M urea slab gel of the RsaI/ClaI fragment: (A) untreated DNA, (B) EcoRIcut, (C) Maxam-Gilbert G + A ladder, (D) Maxam-Gilbert G + A ladder, and (E) reduced PBI-A cleavage ladder.

lung, colon, CNS, melanoma, ovarian, and renal show varying degrees of sensitivity to PBI-A—melanoma appears to be the type of cancer most sensitive to this agent. The *in vivo* screening results obtained thus far show some correlation with the *in vitro* results shown in Table I. For example, PBI-A had no activity against ip-implanted P-388 leukemia in female CD2F1 mice.<sup>2</sup> On the other hand, the growth of HCT-116 colon tumor xenographs in athymic nude mice was substantially inhibited by PBI-C. In contrast, PBI-A treatment of athymic nude mice implanted with HCT-13 colon tumor resulted in no inhibition of

Chart I

Skibo and Schulz



**Figure 2.** Autoradiogram of 8% polyacrylamide/7 M urea slab gel of the *RsaI/Eco*RI fragment showing bases 4310 (top) to 4332 (bottom): (A) treatment with 2.3 M dithionite, (B) treatment with reduced 4.8 mM PBI-A, (C) treatment with aerobic/reduced 3.48 mM PBI-A, (D) treatment with reduced 1.39 mM PBI-A, (E) treatment with 0.69 mM PBI-A, and (F) Maxam-Gilbert G ladder. All treatments A-E were carried out as described in ref 9 except the PBI-A was left out in (A) and aerobic conditions were employed in (C).

tumor growth and PBI-C treatment of the same mice implanted with RXF-393 renal tumor likewise resulted in no inhibition of tumor growth. PBI-A was found to increase the life span of mice ip-implanted with LOX IMVI melanoma by 47%, however.

The COMPARE computer program has been developed by the National Cancer Institute to compare mean graphs of cancer drugs.<sup>18</sup> Generally, cancer drugs with similar mechanisms of action have similar mean graphs. Thus the adriamycin IC<sub>50</sub> mean graph compares well with those of the structurally related deoxydoxorubicin and daunomycin (0.882 and 0.859 correlations coefficients, respectively). Similarly, the alkylating agents chlorambucil, thiotepa, and triethylenemelamine have nearly identical IC<sub>50</sub> mean graphs.<sup>17</sup> The data in Table I did not compare well with any known antitumor agent. The highest correlations obtained were 0.66 with the anthracycline deoxydoxorubicin, 0.628 with the aziridine derivative triethylenemelamine, 0.591 with the anthracycline daunomycin, and 0.589 with the topoisomerase inhibitor AMSA.



#### Table I. Mean Graph LC<sub>50</sub> Data for PBI-A

Latentia CCRP-CEM K-52 MOLT-4 Nes-Small Cell Lang Concer Adsign/TCC EVX HOP-13 HOP-13 HOP-13 HCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M NCH-1322M HCT-116 HCT	Panel/Cell Line	Log LCS0	LC50
CCP-CEM     > 4.00       K.52     > 4.00       MotT-4     > 4.00       NerSmall Call Lang Concer     3.44       HOP22     - 3.43       HOP23     - 4.00       NCH123     < 4.00	Leukemis		· · · · · · · · · · · · · · · · · · ·
x - 5.22     > - 4.00       MOLT-4     > - 4.00       Nor-Small Call Lang Cancer     - 5.44       A589/ATCC     - 5.44       BVX     - 6.30       HOP-12     - 6.44       HOP-32     - 7.09       NCH123     < 4.00	CCRF-CEM	> -4.00	
Mot.T-4         > 4.00           Ner-Small Cell Lang Cancer         5.44           Assynch TCC         5.44           BKYX         4.53           HOP-13         4.64           HOP-32         3.14           HOP-32         3.14           HOP-32         7.09           NCI-1122M         < 4.00	K-562	> -4.00	
Non-Stabl Coll Lang Cancer     544       AS96/TCL     544       HOP-12     4.53       HOP-12     4.54       HOP-13     4.54       HOP-14     4.53       HOP-15     4.54       HOP-16     4.50       HOP-17     5.14       NCH-122     4.50       NCH-123     4.53       NCH-123     4.50       NCH-123     4.50       Small Call Lang Cancer     7.56       DMS 114     7.66       DMS 1273     4.50       Call Cancer     7.64       SW-700     4.52       GLD 2059     7.56       HCT-136     4.54       HCT-136     4.54       HCT-136     4.54       HCT-136     7.56       SW-73     7.53       SW-73     7.53       SW-73     7.54       SW-73     7.53       JCD DNYH     4.50       MABMEL     5.12       JCD DWH     4.50       MABMEL     5.12       JCD DWH     4.50       M14     4.50       M15-MEL     5.12       SK-MEL23     7.73       SK-MEL24     7.41       SK-MEL25     4.50       OVCAR-1 <td>MOLTA</td> <td>&gt; 4.00</td> <td></td>	MOLTA	> 4.00	
A. 369/ATCC     3.4       BKVX     4.53       HOP-15     4.54       HOP-25     4.50       HOP-32     5.14       HOP-32     5.14       HOP-32     4.50       NCLH226     7.709       NCLH221     4.53       NCLH222     4.50       LSFL-391L     7.33       Small Cell Lang Cancer     7.66       DMS 114     -       DMS 273     6.03       Cold Cancer     -       COLO 205     1       DLD-1     1       HCT-116     -       HCT-13     4.03       HCT-14     -       HCT-13     4.03       SNB 273     -       SNB 39     -       SNB 19     -       SNB 19     -       SNB 73     -       SNB 74     -       M14     -       M200     -       OVCAR3     -       OVCAR4     -       OVCA	Non-Smell Call Luna Cancer		
BYX NC     4.33       HOP-18     4.43       HOP-22     -5.14       HOP-23     -7.99       NCI-H323     -6.30       NCI-H324     -6.30       LSPL-5292     -7.33       DMS 114     -7.33       DMS 114     -7.40       DMS 1273     -4.50       Colo 2025     -7.41       DLD-1     -7.64       HCT-115     -7.02	A SAD/A TCC	.5 44	
BKA:s         -244           HOP12         -343           HOP12         -400           HOP12         -400           HOP12         -400           NCH122M         -401           NCH122M         -403           NCH122M         -403           NCH122M         -400           DMS 114         -400           DMS 273         -733           Smill Coll Leg Concer         -744           DMS 273         -745           DLD-1         -422           HC7-135         -746           HC7-135         -744           HT73         -544           SR-35         -547           SF235         -739           UAX DW1         < 400		444	
HOP-18     -3-24       HOP-22     -3.14       HOP-22     -4.03       HOP-22     -4.03       HOP-22     -4.03       HOP-22     -4.03       HOP-22     -4.04       JMS 14     -7.02       JMS 14     -7.02       HCT-115     -7.02       HCT-115     -7.02       HCT-115     -7.02       HCT-115     -7.02       HCT-115     -7.02       KM12     -7.04       SN-73     -7.75       SN-73     -7.75       SN-73     -7.75       SN-73     -7.74       Mellators     -4.00       M4ME-24     -7.19       VCAR-3     -7.34       M4ME-24     -7.35       SNMEL-3     -4.00       VCAR-3     -7.34	EKVA Vod 10		1
HOP-22       3.14	HOP-18	-0.04	
NCH322     -3.14       NCH322     -3.09       NCH322     -4.00       Smill Call Lang Cancer     -7.33       DMS 373     -2.44       Cake Cancer     -7.45       Column 2     -7.33       Smill Call Lang Cancer     -4.00       DMS 373     -4.82       Cake Cancer     -4.00       Column 2     -4.82       MCT-13     -4.82       HCT-14     -7.66       HCT-15     -7.66       HCT-14     -7.66       HCT-13     -7.66       HCT-14     -7.66       HCT-15     -7.66       SP-238     -7.67       SP-238     -7.64       SP-238     -7.24       SP-238     -7.24 <td>HOP-62</td> <td>&lt; -8.00</td> <td></td>	HOP-62	< -8.00	
NCH226     -7.09       NCH233     < 4.00	HOP-92	•5.14	
NCH32M     < 4.00	NCI-H226	•7.09	
NCH322M     < 4.53	NCI-1123	< -8.00	
NCH452     < 4.00	NCI-H322M	-6.63	
LOCP. 529L     7.33       Small Call Lang Cancer     > 4.00       DMS 114     > 4.00       DMS 373	NCI-H522	< -8.00	
Small Call Lang Cancer     > 4.00       DMS 273	LXFL-529L	.7.33	
DMS 114     > 4.00       DMS 273	Smail Cell Lung Cancer		
DNS 373	DMS 114	> -4.00	
Color     Color       COLO 205     JLD-1       JLC-101	DMS 273		1
COLO 205     4.82       DLD-1     4.82       HCT-116     7.66       HCT-115     4.03       HCT-116     -7.02       KM202     4.64       SW-820     4.22       CNS Cancer     -5.67       SF295     -7.29       SNB-73     -7.39       SNB-73     -3.39       U21     -4.54       Malanoma     -4.53       LOX IMVI     -7.24       MALME-3M     -4.50       M4LME-3M     -7.24       M14     -4.00       M14     -5.01       M14     -5.02       SK-MEL-23     -7.29       SK-MEL-23     -7.21       SK-MEL-23     -7.29       SK-MEL-23     -7.29       SK-MEL-23     -7.29       SK-MEL-23     -7.29       SK-MEL-23     -7.29       SK-MEL-23     -7.29       OVCAR-3     -7.24       OVCAR-4     -7.19       OVCAR-5     -5.31       O	Colon Cancer		
DLD-1.007     4.82       IIICC-2998     7.66       HCT-116     7.66       HCT-13     7.02       KM202.1     4.64       SW-600     4.22       CNS Cancer     5.67       SF-268     5.67       SP-268     5.67       SNB-75     5.39       SNB-75     5.39       SNB-75     5.39       UZ31     7.26       M4     < 4.00	COL 0 205		
JUCC 2098     7.56       HCT-116     7.60       HCT-115     4.61       HCT-115     4.63       KM12     7.62       KM2012     4.64       SW-600     4.22       CNS Cancer     5.67       SP-293     7.29       SNB-73     7.39       SNB-73     4.47       SNB-73     7.39       U251     4.53       KM14     < 4.00	DÍ D.1		
HCT-116     HCT-15       HCT-15     -7.02       KM2012     -5.61       SW-600     -4.22       CNS Cancer     -5.67       SF-205     -4.41       SNB-73     -7.56       Malancera     -7.09       LOX MV1     -7.41       M14     -4.00       M19-MEL     -3.12       SK-MEL-28     -7.59       SK-MEL-23     -7.51       SK-MEL-24     -7.61       SK-MEL-25     -7.60       OVCAR-3     -7.36       OVCAR-3     -7.36       OVCAR-5     -7.36       OVCAR-6     -7.36       OVCAR-8     -7.09       SNLC 7.31     -7.35       SNLC 7.31     -7.36       ACHN     -5.33       OVCAR-8     -7.09       OVCAR-8     -7.09       SNLC 7.11     -3.35       OVCAR-8     -7.36       ACHN     -5.35 <t< td=""><td>100.3008</td><td>7.44</td><td></td></t<>	100.3008	7.44	
HCT-15         HT29       6.03         KM12       7.02         KM2012       4.64         \$\$F208       5.67         \$\$F239       7.89         \$\$F239       7.89         \$\$NB-73       7.56         \$\$NB-73       7.54         \$\$NB-73       7.54         \$\$NB-78       -3.39         U251       -5.33         WALMELM       -7.26         MALMETM       -4.00         VALMETMETM       -4.00         VALMETMETM       -4.00         VALMETMETM       -4.00	11CC-2370	*7.00	
HT125       4.03       -7.02         KM12       -7.02       4.64         SW-600       -4.22       -         CNS Conser       -5.67       -         SP-285       -4.47       -         SNB-73       -7.59       -         SNB-73       -7.59       -         SNB-73       -7.59       -         SNB-73       -7.59       -         Malamore       -       -         LOX INVI       -       -         MALME-3M       -       -         M14       -       -         M18-MEL       -       -         SK-MEL2       -       -         SK-MEL3       -       -         UACC-257       -       -         UACC-257       -       -         UCROV1       -       5.25       -         OVCAR-3       -       -       - <td></td> <td>Ì</td> <td>1</td>		Ì	1
N122     -0.03       KM102     -7.02       SW-620     -2.22       CNS Cancer     -5.67       SF-268     -5.67       SF-268     -5.67       SNB-73     -7.58       SNB-73     -7.54       SNB-73     -7.54       U201     -6.64       NMALME-37     -7.59       Walancer     -7.20       M4     -7.20       M14     -7.20       M14     -7.20       M14     -7.20       M14     -7.20       SR-MEL-28     -7.59       SR-MEL-3     -7.59	HCI-IS	l	
KM2L2     -7.02       SW-200     -6.44       SW-200     -6.42       SF268     -6.47       SP-205     -7.89       SNB-19     -6.64       SNB-73     -7.56       SNB-73     -7.56       SNB-73     -7.56       SNB-73     -7.56       SNB-73     -7.50       U201     -6.33       WALME-3M     -7.26       M44     -4.00       M19-MEL     -5.12       SK-MEL-2     -7.41       SK-MEL-28     -7.59       SK-MEL-28     -7.59       SK-MEL-28     -7.59       SK-MEL-28     -7.39       JUACC-62     -7.39       OVCAR-3     -7.39       OVCAR-3     -7.39       SK-OV3     -5.35       SK-OV3     -1.1       SK-NEL     -1.1       SK-DE	H129	-0.03	
NAULL2     -0.44       SV-620     -6.22       CNS Cancer     -5.67       SP-295     -7.49       SNB-73     -7.54       SNB-73     -7.54       J201     -6.53       LOX INVI     -7.26       Malanoma     -       LOX INVI     -7.26       Malanoma     -       LOX INVI     -7.26       MALME-3M     -       M44     -       SK-MEL2     -7.41       SK-MEL28     -7.59	KM12	•7.02	
SW-520     -5.22       CNS Concer     -3.67       SP-283     -4.47       SNB-19     -5.64       SNB-73     -7.29       SNB-73     -5.33       U231     -5.33       XF 498     -7.29       Milamora     -4.00       MALME-3M     -7.26       M13-MEL     -5.12       SK-MEL-2     -7.61       SK-MEL-28     -7.59       SK-MEL-3     -4.00       UACC-62     -4.00       OVCAR-3     -7.34       OVCAR-3     -7.35       OVCAR-4     -7.19       OVCAR-8     -7.09       SK-0V-3     -5.35       Rend Concer     -7.36       7.12     -7.12       OVCAR-8     -7.09       SN12C     -7.12       SN12C     -7.12       SN12C     -7.12       SN12C     -7.12       SN12C     -1       SN12C     -1	KM20L2	-6.54	
CNS Cancer     5.57       SF-235     5.57       SF-235     -5.47       SNB-19     -5.64       SNB-75     -5.39       U251     -5.39       XP 498     -7.26       M4Laroma     < 4.00	SW-620	-6.22	
SF-268     -5.67       SF-268     -6.47       SF-399     -7.89       SNB-19     -6.64       SNB-73     -7.36       SNB-73     -5.33       U231     -5.33       U231     -5.33       XP 498     -7.29       Milamora     -       LOX IMVI     -       MALME-3M     -       M14     -       M14     -       SK-MEL-2     -       SK-MEL-23     -       SK-MEL-23     -       SK-MEL-23     -       SK-MEL-24     -       UACC-257     -       UACC-62     -       OVCAR-3     -       OVCAR-5     -       OVCAR-5     -       OVCAR-6     -       OVCAR-7     -       Struct     -       OVCAR-8     -       Struct     -       OVCAR-8     -       OVCAR-8     -       Struct     -       OVCAR-8     -       Struct     -       OVCAR-8     -       Struct     -       OVCAR-1     -       OVCAR-3     -       Struct     -       OVCAR-1     <	CNS Cancer	******	
SF-235     -5.47       SF-235     -7.59       SNB-19     -5.44       SNB-75     -7.56       SNB-73     -5.39       UZ1     -5.39       Melanora     -       LOX IMVI     < -6.00	SF-268	-5.67	
SP-339     7.39       SNB-19     -5.64       SNB-73     -5.33       U231     -5.33       XF 498     -7.09       Malatoma     -7.26       LOX IMVI     < 4.00	SF-295	-6A7	•
SNB-19     -5.64       SNB-73     -7.56       SNB-78     -5.39       UZ51     -6.53       XF498     -7.26       Melanora     -7.26       LOX IMVI     < 4.00	SF-539	-7.89	
SNB-73     -7.56       SNB-78     -5.39       U231     -5.39       XF 498     -7.29       Malmoraa     -7.26       LOX IMVI     -7.26       MALME-3M     -7.25       M14     -7.26       SK-MEL-2     -7.59       SK-MEL-23     -7.59       SK-MEL-24     -7.51       UACC-62     -7.59       OvcAR-3     -7.19       OVCAR-3     -7.36       OVCAR-4     -7.19       OVCAR-5     -7.36       OVCAR-6     -7.36       OVCAR-7     -6.33       OVCAR-8     -7.36       OVCAR-8     -7.36       OVCAR-8     -7.36       OVCAR-1     -5.33       OVCAR-3     -7.36       OVCAR-3     -7.36       OVCAR-4     -7.12       OVCAR-5     -7.36       OVCAR-6     -7.36       OVCAR-7     -4.00       OVCAR-8     -7.36       SN12C     -7.12       TK-10     -6.26       UAC     -4.00 </td <td>SNB-19</td> <td>-6.64</td> <td></td>	SNB-19	-6.64	
SNB-78     -5.33       U231     -5.33       XF 498     -7.59       Melenoma     -       LOX INVI     -       MALME-3M     -7.26       M14     -       M19-MEL     -5.12       SK-MEL-2     -7.61       SK-MEL-28     -7.59       SK-MEL-5     -       UACC-277     -       UACC-62     -       OVCAR-3     -       OVCAR-4     -       OVCAR-5     -       OVCAR-8     -       SK-04     -       ACHN     -       CACHN     -       SNI2C     -       TK-10 <td>SNB-75</td> <td>-7.56</td> <td></td>	SNB-75	-7.56	
U231     4-53       XP 498     -7.09       Melanoma     < 4.00	SNB-78	-5.39	
XF 498     -7.09       Molenoma     -7.26       LOX INVI     < 4.00	U251	-6.53	d d
Melanora	YEAR	.7.09	
LOX IMVI     < 4.00	Melanama		
MALME-3M     -726       M14     -5.12       Mi-MEL     -7.51       SK-MEL-28     -7.59       SK-MEL-3     < 4.00	I OX IMVI	<	
M14     < 4.00	MAI ME.TM	.7.26	
M19-MEL     5.12       SK-MEL-2     -7.51       SK-MEL-3     -7.53       SK-MEL-5     < 4.00	MILAND-SM	1	
MIS-MEL     3.14       SK-MEL-23     -7.61       SK-MEL-23     -7.59       SK-MEL-3     < 4.00	M14 3410 MET	512	
SK-MEL-2 $-7.59$ SK-MEL-3       < 4.00	er voi a	-7.61	
SK-MEL-28	SK-MEL-2	7.60	
SK-MEL-3       < 4.00	SK-MEL-28	-/ 39	
$\begin{array}{c ccccccc} UACC-22/\\ UACC-62\\ Ovarian Cancer\\ 1 GROV1\\ OVCAR-3\\ OVCAR-4\\ OVCAR-4\\ OVCAR-5\\ OVCAR-8\\ SK-OV-3\\ Remai Cancer\\ 786-0\\ ACHN\\ CAKI-1\\ RXF-933\\ CAKI-1\\ RXF-933\\ SN12C\\ TK-10\\ UO-31\\ \hline \\ MG_MID\\ Deta\\ Range\\ \hline \\ MG_MID\\ Deta\\ Range\\ \hline \\ \\ MG_MID\\ Deta\\ Range\\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	SK-MEL-3	< -0.W	
UACC 62 $\langle -4.00 \rangle$ Ovrain Cancer       -5.85         IGROV1       -6.34         OVCAR-3       -7.19         OVCAR-4       -7.19         OVCAR-8       -7.09         SK-0V-3       -6.36         Renal Cancer       -7.36         786-0       -6.33         ACHN       -6.33         CAK1-1       -5.35         RXP-393       < -8.00	UACC-257	-0./1	
Overain Cancer       -5.85         IGROV1       -5.85         OVCAR-3       -7.19         OVCAR-4       -7.19         OVCAR-5       -7.09         SK-OV-3       -6.33         Renal Cancer       -7.36         786-0       -6.33         ACHN       -6.33         CAKI-1       -5.33         RXP-631       -7.12         SN12C       -7.12         UO-31       -6.61         MG_MID       -6.61         Delta       1.39         Range       4.00	UACC-62	< -8.00	
IGROV1       -3.85         OVCAR-3       -5.35         OVCAR-4       -7.19         OVCAR-5       -6.35         OVCAR-8       -7.36         SK-OV-3       -6.33         ACHN       -6.33         CAKI-1       -5.35         RXF-393       < -8.00	Ovarian Cancer		***************************************
$OVCAR.3$ -5.34 $OVCAR.4$ -7.19 $OVCAR.5$ -6.53 $OVCAR.8$ -7.09 $SK \cdot OV.3$ -6.36         Renel Cancer       -7.36         786-0       -6.33         ACHN       -6.33         CAK11       -5.53         RXP-631       -7.12         SNI2C       -7.12         TK-10       -6.66         UO-31       -< 4.00	IGROV1	-5.85	
OVCAR-4       -7.19         OVCAR-5       -5.33         OVCAR-8       -7.09         SK-OV-3       -6.35         Remail Cancer       -7.36         786-0       -6.33         ACHN       -6.33         CAKI-1       -5.33         RXP-631       -7.12         SN12C       -7.12         TK-10       -6.06         UO-31       -6.61         Delta       1.39         Range       4.00	OVCAR-3	-6.34	
OVCAR-5 OVCAR-8 SK-OV-3     -6.53 -7.09       Renal Cancer 786-0 ACHN     -7.36 -6.53       CAK1-1 RXF-393     -6.53 -7.36       RXF-393     < 4.00	OVCAR-4	-7.19	
$OVCAR.8$ -7.09         SK-OV-3       -5.35         Rend Cancer       -7.36         786-0       -6.53         ACHN       -5.53         CAK11       -5.53         RXF-631       -7.12         SN12C       -7.12         TK-10       -6.66         UO-31       -< -8.00	OVCAR-5	-6.53	4
SK-OV-3       -6.36         Remail Cancer       -7.36         786-0       -6.33         ACHN       -5.33         CAKI-1       -5.53         RXF-631       -7.12         SN12C       -7.12         TK-10       -6.06         UO-31       -6.61         Delta       1.39         Range       4.00	OVCAR-8	-7.09	
Renal Cancer     -7.36       786-0     -6.53       ACHN     -5.33       CAK1-1     -5.33       RXF-393     < -8.00	SK-OV-3	-6.36	=
786-0     -7.36       ACHN     -6.53       CAK11     -5.53       RXF-631     < -8.00	Renal Cancer	·	*** ***
ACHN CAKI-1 RXF-393 RXF-631 SNI2C TK-10 UO-31 MG_MID Delta Range ACHN -5.33 -5.33 -5.33 -7.12 -6.06 -< -8.00 	786-0	-7.36	
CAKI-1       -5.53         RXF-393       < -8.00	ACHN	-6.53	4
RXF-393     < -8.00	CAKI-1	-5.53	
RXP-631     -7.12       SN12C     -7.12       TK-10     -6.66       UO-31     -<	RXF-393	< -8.00	
SN12C     -7.12       TK-10     -6.05       UO-31     -6.61       Delta     1.39       Range     4.00	RXF-631		
TK-10 UO-31 MG_MID Delta Range 4.00 +3 +2 +1 0 -1 -2	SNI2C	.7.12	
UO-31     -< -8.00	776.10	4.04	
MG_MID Delta Ranga 4.00 +3 +2 +1 0 -1 -2 -	10.31	0.00	
MG_MID Delta Range 4.00 +3 +2 +1 0 -1 -2	00.31	· · · ····	
Total     1.39       Delta     1.39       4.00     1       +3     +2       +1     0       -1     -2		4 41	
Range 4.00 -1 -2 -	Delte	1 20	
4.00 -1 -2 -	Detta	1.59	
+3 +2 +1 0 -1 -2 -	Karige	4.00	
+3 +2 +1 0 -1 -2 -		j Ļ	
		+3	+2 +1 0 -1 -2 -3
		1	
		1	
		J	

Significantly, previous comparative studies with a single cell line resulted in the conclusion that PBI-A had anthracycline-like properties.<sup>2</sup> Probably the greatest point of difference between the PBI analogues and other antitumor agents is the complete absence of PBI activity against leukemia.

## Conclusion

Some aspects of PBI-mediated DNA cleavage are consistent with a mechanism involving phosphate backbone alkylation followed by hydrolytic cleavage. Thus PBI DNA adducts are stable to hydrolysis and require heating in base in order to see DNA cleavage. In contrast, N(7)-DNA adducts are readily removed by hydrolysis.<sup>10</sup> The results of model studies with a PBI-5'dAMP adduct are consistent with a mechanism involving phosphate alkylation followed by hydrolysis. Other aspects of PBImediated DNA cleavage could be interpreted in terms of a mechanism involving N(7) alkylation, however. Thus, PBIs mediate G + A cleavage and produce 5'-phosphate cleavage termini, both of which are observed in aziridinylquinones known to alkylate DNA at the N(7)-position.<sup>5</sup> It is therefore possible that PBIs cleave by N(7) and by phosphate alkylation mechanisms. Indeed, Bannon and Verly<sup>10</sup> found the alkyl methanesulfonates can alkylate DNA at both positions.

The PBIs possess a unique spectrum of cytotoxic activity, which may or may not be related to the mechanism

of DNA cleavage. Previous studies<sup>2</sup> showed that cytotoxicity is due to the presence of DNA cleavage, however. Consistent with PBI cytotoxicity, analogues are shown to possess in vivo antitumor activity, which parallels the spectrum of activity observed in cell lines.

Further studies of DNA-PBI interactions and of PBI in vivo antitumor activity are in progress: nine PBI are currently in in vivo trials at the National Cancer Institute. We will report on the results of these studies in due course.

#### **Experimental Section**

Buffer salts, EDTA, and urea were purchased from Sigma and used as is. Acrylamide and methylene bisacrylamide were purchased from BioRad in 99.9% pure form. pBR322 DNA, EcoRI, RsaI, and Klenow fragment were purchased from New England Biolabs. <sup>32</sup>P Labeled CTP and ATP were purchased from Dupont. Buffers and other solutions were prepared in doubly distilled water. DNA restriction fragments were purified and end labeled using previously reported procedures.<sup>8</sup>

PBI cleavage of DNA was carried out as follows: In a 1.5-mL microfuge tube were combined 1  $\mu$ L labeled DNA (10 000 cpm),  $1 \,\mu\text{L}$  of  $10 \,\mu\text{g/mL}$  cold DNA (pBR322),  $1 \,\mu\text{L}$  of PBI-A stock (1.3 mM in 0.05 M pH 7.4 Tris buffer), and  $6 \,\mu$ L of pH 7.4 Tris buffer. This solution was degassed for 15 min with argon and followed by addition of 1  $\mu$ L of sodium dithionite (34 mM). We found that dithionite itself will react with reduced PBI-A, and therefore excessive amounts of PBI-A were used in the cleavage study. Nevertheless, dithionite is a convenient reducing agent for limited cleavage experiments. The reaction was incubated for 30 min at 37 °C under an argon atmosphere, and then to the reaction mixture was added 1  $\mu$ L of 3 M sodium acetate pH 5.2 (0 °C) followed by 30  $\mu$ L of ethanol (-20 °C). The solution was chilled for 15 min at -70 °C and then centrifuged at 12 000 g for 20 min. The supernatant was then carefully decanted from the DNA pellet. To the pellet was added 100  $\mu$ L of ethanol (-20 °C) followed by centrifuging at 12 000 g for 5 min. After decanting the ethanol, the pellet was vacuum dried and combined with 5  $\mu L$  of sequence gel loading buffer, which was prepared by combining 800  $\mu$ L of formamide, 100  $\mu$ L of 0.1 N NaOH, 100  $\mu$ L double distilled H<sub>2</sub>O, and 1 mg each of xylene cyanol and bromophenol blue. The mixture was electrophoresed on 21 cm long  $\times$  0.25 mm thick 8% acrylamide (29:1, acrylamide to methylene bisacrylamide) 7 M urea denaturing gel employing 0.089 M pH 8.3 Tris borate buffer containing 25 mM of EDTA. The gel was run at 1700 V for 2 h.

Preparation of Blue DNA. To a solution of 70 mg of sonicated calf thymus DNA in 20 mL of pH 7.4, 0.05 M Tris buffer was added 20 mg PBI-A, dissolved in 2 mL of dimethyl sulfoxide, and 10 mg of 5% Pd on carbon. The mixture was degassed with argon, and then a stream of H<sub>2</sub> passed through the solution for 10 min. After reduction was complete (solution went from red to colorless), the excess H<sub>2</sub> was removed by purging with argon, and the reaction was incubated at 37 °C for 24 h. The reaction was opened to the air and extracted 3× with 50-mL portions of chloroform to remove hydrolysis products, and the aqueous layer was adjusted to 0.3 M sodium acetate (pH 5.1). The DNA pellet was obtained by diluting the sodium acetate solution with 3 volumes of ethanol, chilling the solution overnight at -20 °C, and finally centrifuging at 12 000 g for 20 min. The pellet was suspended in 100% ethanol and centrifuged at 12 000 g for 5 min and then dried, yield: 60% DNA recovered.

Reaction products were studied by HPLC on an ISCO 5  $\mu$ m SAX reverse phase column, with 0.8 M KH<sub>2</sub>PO<sub>4</sub> mobile phase, and the products were isolated by means of a Phenyl Bakerbond reverse phase column with aqueous methanol as the mobile phase. All the products derived from PBI were formed by hydrolysis. The structures of these products and their mechanism of formation will be the subject of another study.

Preparation of PBI 5'-dAMP Adduct. To a solution of 124.7 mg (0.289 mmol) of 5'-dAMP hydrated sodium salt in 20 mL of pH 7.4, 0.05 M Tris buffer was added 30 mg (0.115 mmol) of PBI (Z = OH), dissolved in 2 mL of dimethyl sulfoxide, and 10 mg of 5% Pd on carbon. Degassing and reduction was carried

out as described above, and the reaction was incubated at 37 °C for 22 h. The reaction was opened to the air, filtered through Celite, and then placed on a 20-g Phenyl Bakerbond column prepared with water. The aminoquinone nucleotide adduct eluted from the column with water as the first blue band. The isolated product was rechromatographed on a 10-g column to remove 5'-dAMP, yield ~6 mg (8.5%). No other quinonenucleotide adduct was formed in the reaction. Both <sup>1</sup>H NMR and <sup>31</sup>P NMR studies indicate that alkylation of phosphate oxygen. had occurred: <sup>1</sup>H NMR dimethyl- $d_6$  sulfoxide  $\delta$  8.39 (1H, brs, C(8) adenine), 8.13 (1H,s, C(2) adenine), 7.65 and 7.00 (2H, 2brs, C(3') hydroxy of 5'-dAMP, C(6) amino of PBI), 7.24 (2H, brs, C(6) adenine amine), 6.35 (1H, t, C(1') anomeric proton, J = 6Hz), 5.85 (1H, d, C(3) hydroxy, J = 6 Hz), 4.94 (1H, m, C(3) proton), 4.44 (1H, m, C(3')), 4.17 and 4.07 (2H, 2m, C(1) diastereomeric methylene), 3.94 (1H, d, C(4'), J = 2.5 Hz), 3.83(4H, m, C(6) ethyl bridge), 3.69 (2H, q, J = 5 Hz, C(5')), 2.86 and2.35 (2H, 2m, C(2) diastereomeric methylene), 2.73 and 2.26 (2H, 2m, C(2') diastereomeric methylene), 1.93 (3H, s, C(7) methyl). Note that the amino group of adenine (two protons) is present and therefore amine alkylation could not have occurred. <sup>81</sup>P NMR (D<sub>2</sub>O) provided a chemical shift of  $\delta$  3.46 (vs phosphoric acid) for the quinone nucleotide and a chemical shift of  $\delta$  6.98 (vs phosphoric acid) for 5'-dAMP. The 3.5 ppm upfield shift in the phosphorus resonance indicates that the quinone nucleotide is a phosphodiester.<sup>19</sup>

Antitumor Studies. Response of subrenal capsule HCT-116 colon tumor xenografts to PBI-C at 15 mg/Kg administered intraperitoneally every 4 days, starting on day 2 after tumor implantation, for a total of three treatments resulted in a T/C%value of 5, which indicates tumor inhibition (T/C%) is defined as  $(\Delta T/\Delta C) \times 100$  where  $\Delta T$  is the change in tumor weight in treated mice and  $\Delta C$  is the change in tumor weight in control mice).

Responses of HCT-13 colon and RxF-303 renal implants to PBI-A and PBI-C, respectively were in the inactive range, T/C%> 10.

Response of ip-implanted LOX IMVI melanoma to 6.0 mg/kg dose of PBI-A administered intraperitoneally every 4 days, starting on day 1 after tumor implantation, for a total of three treatments was to increase life span 47% over controls.

Acknowledgment. We thank the American Cancer Society for generous research support, the National Institutes of Health for a research career development award (to E.B.S. 1988-1993), and the Division of Cancer Treatment of the National Cancer Institute for supplying antitumor data. Also, we wish to thank one of the reviewers for carefully reviewing both the initial and revised versions of this manuscript.

#### References

- (1) Islam, I.; Skibo, E. B. Synthesis and Physical Studies of Azamitosene and Iminoazamitosene Reductive Alkylating Agents. Iminoquinone
- and immodiation reductive Arkylating Agents. Immodulinone Hydrolytic Stability, Syn/Anti Isomerization, and Electrochemistry. J. Org. Chem. 1990, 55, 3195-3205.
  (2) Islam, I.; Skibo, E. B.; Dorr, R. T.; Alberts, D. S. Structure-Activity Studies of Antitumor Agents Based on Pyrrolo-[1,2-a]benzimidazoles: New Reductive Alkylating DNA Cleaving Agents. J. Med. Chem. 1991, 34, 2954-2961.
  (2) Skiba E. B. Joury, L. Surabacia di Elucidada e ad Americana.
- Skibo, E. B.; Islam, I. Synthesis and Elucidation and Azamitosene (3) and Iminoazamitosene. U.S. Patent 5,015,742.
- For commentary on these antitumor agents, see: Hollis Showalter, H. D. Structure-Activity Studies of Antitumor Agents Based on Pyrrolo[1,2-a]benzimidazoles: New Reductive Alkylating DNA Cleaving Agents. Chemtracts-Organic Chemistry 1992, 5, 166-170.
- (a) Hartley, J. A.; Berardini, M.; Ponti, M.; Gibson, N. W.; Thompson, A. S.; Thurston, D. E.; Hoey, B. M.; Butler, J. DNA Cross-Linking and Sequence Selectivity of Aziridinyl-benzoquinones: A Unique Reaction at 5'-GC-3' Sequences with (5) 2,5-Diaziridinyl-1,4-benzoquinone upon Reduction. Biochemistry 1991, 30, 11 719–11 724. (b) Lee, C.-H.; Hartley, J. A.; Berardini, M. D.; Butler, J.; Siegel, D.; Ross, D.; Gibson, N. W. Alteration in DNA Cross-Linking and Sequence Selectivity of a Series of Aziridinylbenzoquinones and Enzymatic Reduction by DT-Diaphorase. Biochemistry 1992, 31, 3019-3025.

- (6) Ethylnitrosourea (ENU) alkylates DNA phosphates resulting in base-labile phosphotriesters, see references: Nielsen, P. E. In Chemical and Photochemical Probing of DNA Complexes. J. Mol. Recog. 1990, 3, 1-25 (see pp 7 and 8).
- (7) These restriction fragments have a cohesive end suitable for 3' end labeling utilizing the Klenow fragment and either ~.<sup>32</sup>P dATP or ~.<sup>32</sup>P dCTP for the EcoRI or ClaI ends, respectively.
- (8) Maxam, A. M.; Gilbert, W. Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages. *Methods Enzymol.* 1980, 69, 499-560.
- (9) Maniatis, T.; Fritsch, E. F.; Sambrook, J. Molecular Cloning, A. Laboratory Manual; Cold Spring Harbor Laboratory: 1982; pp 479-487.
- (10) Bannon, P.; Verly, W. Alkylation of Phosphates and Stability of Phosphate Triesters in DNA. Eur. J. Biochem. 1972, 31, 103-111.
- (11) (a) Tomasz, M.; Lipman, R. Alkylation Reactions of Mitomycin C at Acid pH. J. Am. Chem. Soc. 1979, 101, 6063-6067. (b) Iyengar, B. S.; Dorr, R. T.; Remers, W. A.; Kowal, C. D. Nucleotide Derivatives of 2,7-Diaminomitosene. J. Med. Chem. 1988, 31, 1579-1585.
- (12) Miller, P. S.; Chandrasegaran, S.; Dow, D. L.; Pulford, S. M.; Kan, L. S. Synthesis and Template Properties of an Ethyl Phosphotriester Modified Decadeoxyribonucleotide. *Biochemistry* 1982, 21, 5468– 5474.

- (13) Conrad, J.; Müller, N.; Eisenbrand, G. Studies on the Stability of Trialkyl Phosphates and Di-(2'-deoxythymidine) Phosphotriesters in Alkaline and Neutral Solution. A Model Study for Hydrolysis of Phosphotriesters in DNA and on the Influence of a β-Hydroxyethyl Ester Group. Chem. Biol. Interactions 1986, 60, 57-65.
- yethyl Ester Group. Chem. Biol. Interactions 1986, 60, 57-65.
  Browne, K. A.; Bruice, T. C. Chemistry of Phosphodiesters, DNA and Models. 2. The Hydrolysis of Bis(8-hydroxyquinoline) Phosphate in the Absence and Presence of Metal Ions. J. Am. Chem. Soc. 1992, 114, 4951-4958.
- (15) Tomasz, M.; Lipman, R.; McGuinness, B. F.; Nakanishi, K. Isolation and Characterization of a Major Adduct Between Mitomycin C and DNA. J. Am. Chem. Soc. 1988, 110, 5892-5896.
- (16) LC<sub>50</sub> data provided by the National Cancer Institute.
- (17) Boyd, M. R. Status of the NCI Preclinical Antitumor Drug Discovery Screen. Principles and Practices of Oncology (PPO updates) 1989, 3, no. 10.
- (18) Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and Analysis of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
- (19) Van Wazer, J. R.; Ditchfield, R. Phosphorus Compounds and Their <sup>31</sup>P Chemical Shifts. *Phosphorus NMR in Biology*; Burt, C. T., Ed.; CRC Press: Boca Raton, FL, 1987; pp 1-23, see Figure 2.